Price Alert

Day One Biopharmaceutical... (DAWN)

NASDAQ: DAWN · Real-Time Price · USD

6.53

0.28 (4.48%)

At close: Aug 15, 2025, 1:22 PM

Day One Biopharmaceuticals Statistics

Share Statistics

Day One Biopharmaceuticals has 102.43M shares outstanding. The number of shares has increased by 15.5% in one year.

Shares Outstanding	102.43M
Shares Change (YoY)	15.5%
Shares Change (QoQ)	0.01%
Owned by Institutions (%)	83.3%
Shares Floating	75.46M
Failed to Deliver (FTD) Shares	973
FTD / Avg. Volume	0.06%

Short Selling Information

The latest short interest is 10.28M, so 10.14% of the outstanding shares have been sold short.

Short Interest	10.28M
Short % of Shares Out	10.14%
Short % of Float	15.09%
Short Ratio (days to cover)	8.59

Valuation Ratios

The PE ratio is -12.42 and the forward PE ratio is -7.83. Day One Biopharmaceuticals's PEG ratio is 0.22.

PE Ratio	-12.42
Forward PE	-7.83
PS Ratio	9.04
Forward PS	2.8
PB Ratio	2.36
P/FCF Ratio	-14.78
PEG Ratio	0.22

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Day One Biopharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.66, with a Debt / Equity ratio of 0.01.

Current Ratio	7.66
Quick Ratio	7.61
Debt / Equity	0.01
Debt / EBITDA	-0.01
Debt / FCF	-0.03
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$724.65K
Profits Per Employee	$-527.6K
Employee Count	181
Asset Turnover	0.23
Inventory Turnover	1.59

Taxes

Income Tax	-7.14M
Effective Tax Rate	8.09%

Stock Price Statistics

The stock price has increased by -56.19% in the last 52 weeks. The beta is -1.27, so Day One Biopharmaceuticals's price volatility has been lower than the market average.

Beta	-1.27
52-Week Price Change	-56.19%
50-Day Moving Average	6.69
200-Day Moving Average	9.76
Relative Strength Index (RSI)	39.79
Average Volume (20 Days)	1,573,993

Income Statement

In the last 12 months, Day One Biopharmaceuticals had revenue of 131.16M and earned -95.5M in profits. Earnings per share was -1.02.

Revenue	131.16M
Gross Profit	125.88M
Operating Income	-217.27M
Net Income	-95.5M
EBITDA	-217.27M
EBIT	-88.35M
Earnings Per Share (EPS)	-1.02

Full Income Statement

Balance Sheet

The company has 124.97M in cash and 2.6M in debt, giving a net cash position of 122.37M.

Cash & Cash Equivalents	124.97M
Total Debt	2.6M
Net Cash	122.37M
Retained Earnings	-554.08M
Total Assets	519.04M
Working Capital	443.21M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -78.11M and capital expenditures -2.17M, giving a free cash flow of -80.28M.

Operating Cash Flow	-78.11M
Capital Expenditures	-2.17M
Free Cash Flow	-80.28M
FCF Per Share	-0.86

Full Cash Flow Statement

Margins

Gross margin is 95.98%, with operating and profit margins of -165.65% and -72.81%.

Gross Margin	95.98%
Operating Margin	-165.65%
Pretax Margin	-67.36%
Profit Margin	-72.81%
EBITDA Margin	-165.65%
EBIT Margin	-165.65%
FCF Margin	-61.21%

Dividends & Yields

DAWN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for DAWN is $27, which is 356.9% higher than the current price. The consensus rating is "Buy".

Price Target	$27
Price Target Difference	356.9%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	5.36
Piotroski F-Score	3